Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

CORONA REMEDIES LTD.

NSE : NABSE : 544644ISIN CODE : INE02ZQ01018Industry : Pharmaceuticals & DrugsHouse : Private

BSE0.000 (0 %)

PREV CLOSE ( ) NA

OPEN PRICE ( ) 0.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 0

TODAY'S LOW / HIGH ( )0.00 0.00

52 WK LOW / HIGH ( ) 00

NSE

This Company is not listed in NSE

Select year

Particulars

Mar 2025

Mar 2024

Mar 2023

Operational & Financial Ratios

Earnings Per Share (Rs)

24.43

14.80

13.89

CEPS(Rs)

30.51

19.42

17.17

DPS(Rs)

7.31

3.70

2.77

Book NAV/Share(Rs)

99.14

78.55

66.80

Tax Rate(%)

24.73

23.61

23.41

Margin Ratios

Core EBITDA Margin(%)

19.71

14.92

14.25

EBIT Margin(%)

17.17

12.82

Pre Tax Margin(%)

16.30

11.42

12.35

PAT Margin (%)

12.27

8.73

9.46

Cash Profit Margin (%)

15.32

11.45

11.69

Performance Ratios

ROA(%)

15.79

11.77

12.82

ROE(%)

27.50

20.36

20.79

ROCE(%)

32.59

25.93

28.03

Asset Turnover(x)

1.29

1.35

1.36

Sales/Fixed Asset(x)

2.47

2.81

3.50

Working Capital/Sales(x)

12.27

15.78

5.83

Efficiency Ratios

Fixed Capital/Sales(x)

0.40

0.36

0.29

Receivable days

32.70

32.89

35.35

Inventory Days

34.14

35.85

42.83

Payable days

198.94

167.89

163.28

Valuation Parameters

PER(x)

0.00

PCE(x)

0.00

Price/Book(x)

0.00

Yield(%)

EV/Net Sales(x)

0.05

0.12

-0.01

EV/Core EBITDA(x)

0.22

0.78

-0.10

EV/EBIT(x)

0.26

0.94

-0.11

EV/CE(x)

0.08

0.20

-0.03

M Cap / Sales

0.00

Growth Ratio

Net Sales Growth(%)

17.93

14.75

0.00

Core EBITDA Growth(%)

52.56

19.37

0.00

EBIT Growth(%)

57.34

15.43

0.00

PAT Growth(%)

65.11

6.56

0.00

EPS Growth(%)

65.11

6.56

0.00

Financial Stability Ratios

Total Debt/Equity(x)

0.10

0.28

0.01

Current Ratio(x)

1.30

1.24

1.74

Quick Ratio(x)

0.91

0.88

1.23

Interest Cover(x)

19.72

9.21

26.98

Total Debt/Mcap(x)